Evidence map›Paper›PMID 28644480›Full record

ArticleNature chemistry2017

A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF

Hiroyuki Koide, Keiichi Yoshimatsu, Yu Hoshino, Shih-Hui Lee, Ai Okajima, Saki Ariizumi, Yudai Narita, Yusuke Yonamine, Adam C Weisman, Yuri Nishimura and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 155 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Current advances in separation chemistry for antibody purification and analysis.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Design of an Anti-HMGB1 Synthetic Antibody forJournal of the American Chemical Society · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Hiroyuki KoideDepartment of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
Keiichi YoshimatsuDepartment of Chemistry, University of California Irvine, Irvine, California 92697, USA.
Yu HoshinoDepartment of Chemical Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan.
Shih-Hui LeeDepartment of Chemistry, University of California Irvine, Irvine, California 92697, USA.
Ai OkajimaDepartment of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
Saki AriizumiDepartment of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
Yudai NaritaDepartment of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-9266-9232
Yusuke YonamineDepartment of Chemistry, University of California Irvine, Irvine, California 92697, USA.
Adam C WeismanDepartment of Chemistry, University of California Irvine, Irvine, California 92697, USA.
Yuri NishimuraDepartment of Chemical Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan.
Naoto OkuDepartment of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
Yoshiko MiuraDepartment of Chemical Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan.
Kenneth J SheaDepartment of Chemistry, University of California Irvine, Irvine, California 92697, USA.
University of California, Irvine · USUniversity of Shizuoka · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein affinity reagents are widely used in basic research, diagnostics and separations and for clinical applications, the most common of which are antibodies. However, they often suffer from high cost, and difficulties in their development, production and storage. Here we show that a synthetic polymer nanoparticle (NP) can be engineered to have many of the functions of a protein affinity reagent. Polymer NPs with nM affinity to a key vascular endothelial growth factor (VEGF

Indexed as

Protein EngineeringCell ProliferationDose-Response Relationship, DrugHumansHuman Umbilical Vein Endothelial CellsNanoparticlesPolymersVascular Endothelial Growth Factor APolymersVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID28644480
OpenAlexW2598358736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.